2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Eli Lilly company profile · tirzepatide · business segments · history · financial snapshot · S&P 500 rank #11 · 禮來公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | LLY (NYSE) |
| Company | Eli Lilly and Company |
| GICS sector / industry | Health Care (XLV) / Pharmaceuticals |
| S&P 500 rank (by weight) | #11 · 1.60% (Oct 21, 2026) |
| Sector rank (by market cap) | #1 in Health Care (Oct 16, 2026) |
| Headquarters | Indianapolis, Indiana |
| Founded | May 10, 1876, Indianapolis, Indiana (incorporated 1901) |
| CEO | David A. Ricks (chair, president & CEO since 2017) |
| Employees | ≈50,000 — Dec 31, 2025, FY2025 10-K |
| Market cap | $1,120B (Oct 16, 2026) |
| SEC filings | EDGAR — CIK 0000059478 |
WHAT IT DOES
Eli Lilly and Company — Lilly — is a research-based global pharmaceutical company headquartered in Indianapolis, Indiana. It discovers, develops, manufactures and sells branded prescription medicines in approximately 90 countries, with offices, production and research facilities in 36 countries. Founded in 1876, it employs roughly 50,000 people and is the world's largest drugmaker by revenue.
The money comes from patent-protected branded drugs. In FY2025, net product sales were $60.96B (93.5% of revenue); collaboration and other revenue — profit-sharing, royalties, milestones — added $4.22B (6.5%). The engine is a single molecule: tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea. The two brands did $36.5B combined in FY2025 — 56% of the entire company.
Beyond tirzepatide, the portfolio spans oncology (Verzenio for breast cancer), immunology (Taltz, Omvoh, Ebglyss), neuroscience (Kisunla for early Alzheimer's, Emgality for migraine) and a legacy diabetes franchise (Trulicity, insulins). The United States was 66.7% of FY2025 revenue and Europe 17.7%. The flywheel is R&D reinvestment — $13.3B in FY2025, about one-fifth of revenue, funding 36 active Phase III programs — plus a manufacturing buildout of more than $55B committed since 2020 to keep the incretin supply ahead of demand.
BUSINESS SEGMENTS — FY2025 PRODUCT REVENUE
| Product | Revenue | Share | YoY |
|---|---|---|---|
| Mounjaro (tirzepatide, type 2 diabetes) | $22.97B | 35.2% | +99% |
| Zepbound (tirzepatide, obesity) | $13.54B | 20.8% | +175% |
| Verzenio (abemaciclib, breast cancer) | $5.72B | 8.8% | +8% |
| Trulicity (dulaglutide, type 2 diabetes) | $4.28B | 6.6% | −19% |
| Taltz (ixekizumab, immunology) | $3.56B | 5.5% | +9% |
| Jardiance family (empagliflozin, with Boehringer Ingelheim) | $3.43B | 5.3% | +3% |
| Other cardiometabolic health (incl. insulins) | $4.01B | 6.1% | −10% |
| Other oncology | $3.65B | 5.6% | +6% |
| Other immunology | $1.68B | 2.6% | +49% |
| Neuroscience | $1.39B | 2.1% | −6% |
| Other | $0.94B | 1.4% | +4% |
| Total | $65.18B | 100% | +45% |
Tirzepatide (Mounjaro + Zepbound) is the franchise — a dual GIP/GLP-1 receptor agonist, $36.5B in FY2025 and 56% of revenue. Mounjaro (type 2 diabetes, launched 2022) holds more than 55% of new US diabetes prescriptions; Zepbound (obesity, approved Nov 2023) holds nearly 70% of new US branded obesity prescriptions, with lower-priced vials now about one-third of its scripts.
Verzenio (CDK4/6 inhibitor for breast cancer) is the oncology anchor at $5.72B and still growing. Trulicity, the older once-weekly GLP-1, is fading as tirzepatide cannibalizes it — down 19% in FY2025 to $4.28B.
Taltz (immunology) and the Jardiance family (co-marketed with Boehringer Ingelheim) are steady mid-single-digit growers. The "other" buckets carry the next wave: recently launched Omvoh and Ebglyss in immunology, Jaypirca in oncology, and Kisunla — the anti-amyloid Alzheimer's drug — in neuroscience.
HISTORY
| Year | Milestone |
|---|---|
| 1876 | Colonel Eli Lilly, a Civil War veteran and pharmaceutical chemist, founds the drug business in Indianapolis (incorporated as Eli Lilly and Company in 1901) |
| 1923 | First company to mass-produce insulin (Iletin), working with the University of Toronto researchers |
| 1955 | First to mass-produce the Salk polio vaccine |
| 1982 | Humulin approved — the first recombinant-DNA human insulin and the first biotech drug |
| 1987 | Prozac (fluoxetine) approved — becomes a blockbuster antidepressant |
| 1996 | Zyprexa (olanzapine) approved for schizophrenia and bipolar disorder |
| 2003 | Cialis (tadalafil) approved — becomes a major erectile-dysfunction franchise |
| 2008 | Acquires ImClone Systems for ≈$6.5B, gaining the cancer drug Erbitux |
| 2014 | Acquires Novartis's animal health business for $5.4B, folded into Elanco |
| 2017 | David Ricks becomes CEO |
| 2018 | Elanco animal health business IPO (September) |
| 2019 | Acquires Loxo Oncology for approximately $8.0B (February; $235.00 per share in cash, announced Jan 7, 2019); completes the Elanco split-off (March) |
| 2022 | Mounjaro (tirzepatide) FDA-approved for type 2 diabetes (May) |
| 2023 | Zepbound approved for chronic weight management (November, US) |
| 2024 | Kisunla (donanemab) approved for early Alzheimer's (July, US); Lilly becomes the world's most valuable drugmaker |
| 2025 | Tirzepatide franchise reaches $36.5B (56% of revenue); market cap touches $1T (November), the first health-care company to do so |
| 2026 | Foundayo (orforglipron) — the first oral small-molecule GLP-1 — FDA-approved for obesity (April); record Q2 revenue of $22.97B (+48%); FY2026 guidance raised to $85–87B; announces a $3.5B injectables plant in Pennsylvania (October) |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Revenue | $65.18B (+45% YoY; FY2024 $45.04B) |
| Gross profit / margin | $54.1B · 83.0% |
| Operating income | $26.30B · 40.4% margin |
| Net income | $20.64B · 31.7% margin (+95% YoY) |
| Diluted EPS | $22.95 reported · $24.21 non-GAAP (+86%) |
| R&D expense | $13.3B (20.4% of revenue) |
| Operating cash flow | $16.81B (FY2024 $8.82B) |
| Free cash flow | ≈$6.0B (OCF $16.81B − capex $10.85B) |
| Cash & equivalents | $7.27B (Dec 31, 2025) |
| Total debt | ≈$42.5B — net debt position (debt/equity ≈1.6×) |
| Dividends | $6.00/share (+15% YoY) · $5.38B paid |
| Latest quarter (Q2 2026, ended Jun 30, 2026) | Revenue $22.97B (+48% YoY) · net income $7.10B · diluted EPS $7.94 (non-GAAP $8.38) · gross margin ≈86% |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Lilly is the index's #11 constituent at a 1.60% weight (Oct 21, 2026) — a 1% move in LLY moves the S&P 500 by roughly 1.6 basis points, and it is the single largest name in the Health Care sector by market cap ($1,120B, Oct 16, 2026). In an index dominated by technology, Lilly is the defensive-growth anchor of health care: the sector's bellwether, with a low beta (≈0.43) and the market's purest exposure to the obesity-drug cycle.
For index and options traders: Lilly's quarterly prints (late January / April / July / October) read as a verdict on GLP-1 demand, pricing and supply — moving XLV and the broader health-care complex — and its prescription-share data versus Novo Nordisk is the highest-frequency read on the incretin duopoly available to the market.
SOURCES & METHODOLOGY
| Financials, products, employees, cash/debt | Lilly FY2025 Form 10-K (filed February 2026; fiscal year ended Dec 31, 2025); line items via S&P Capital IQ (FT Markets) and Alpha Spread |
| Product revenue split | FY2025 10-K product disclosures (SEC-filing-based compilation); Mounjaro/Zepbound totals cross-checked with the Q4 2025 earnings release (Feb 4, 2026) |
| Latest quarter (Q2 2026) | Lilly Q2 2026 earnings release (August 5, 2026); quarter ended Jun 30, 2026 |
| Index weight & rank | Slickcharts S&P 500 weights, Oct 21, 2026 close (assignment baseline) |
| Market cap & sector rank | Oct 16, 2026 snapshot (SPXSet Top-25 dataset; assignment baseline) |
| Prescription share, pipeline, guidance | Lilly Q4 2025 earnings call transcript (finviz); FY2026 guidance $85–87B revenue via TipRanks (Oct 20, 2026) |
| History & company facts | Lilly 10-K/10-Q/8-K filings (via findstockfast); Wikipedia company page (facts cross-checked against filings) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | LLY(NYSE) |
| 公司 | Eli Lilly and Company(禮來公司) |
| GICS 板塊/行業 | 醫療健康(XLV)/製藥 |
| 標普500排名(按權重) | #11 · 1.60%(2026年10月21日) |
| 板塊內排名(按市值) | 醫療健康 #1(2026年10月16日) |
| 總部 | 印第安納州印第安納波利斯 |
| 成立 | 1876年5月10日,印第安納波利斯(1901年註冊為公司) |
| 執行長 | David A. Ricks(2017年起任董事長、總裁兼執行長) |
| 員工 | 約50,000名——2025年12月31日,FY2025 10-K |
| 市值 | $1,120B(1.12兆美元,2026年10月16日) |
| SEC 申報 | EDGAR — CIK 0000059478 |
業務概覽
禮來(Eli Lilly and Company)是一家以研發為本的全球製藥公司,總部位於印第安納州印第安納波利斯。公司發現、開發、生產並銷售品牌處方藥,業務遍及約 90 個國家,在 36 個國家設有辦公室、生產與研發設施。創立於 1876 年,員工約 50,000 名,是全球營收最高的製藥公司。
收入來自受專利保護的品牌藥。FY2025 淨產品銷售 $60.96B(609.6億美元,佔營收 93.5%);合作與其他收入——利潤分成、權利金、里程碑款——為 $4.22B(42.2億美元,佔 6.5%)。增長引擎是單一分子:替爾泊肽(tirzepatide),以 Mounjaro 治二型糖尿病、以 Zepbound 治肥胖與阻塞性睡眠呼吸中止。兩品牌 FY2025 合計 $36.5B(365億美元)——佔全公司 56%。
替爾泊肽之外,產品線涵蓋腫瘤(乳癌藥 Verzenio)、免疫(Taltz、Omvoh、Ebglyss)、神經科學(早期阿茲海默症藥 Kisunla、偏頭痛藥 Emgality),以及傳統糖尿病業務(Trulicity、胰島素)。美國佔 FY2025 營收 66.7%,歐洲 17.7%。飛輪是研發再投入——FY2025 研發 $13.3B(133億美元,約佔營收兩成),支撐 36 項三期臨床試驗——以及自 2020 年以來承諾逾 $55B(550億美元)的產能擴建,讓腸泌素產能跑在需求前面。
業務板塊 — FY2025 產品營收
| 產品 | 營收 | 佔比 | 同比 |
|---|---|---|---|
| Mounjaro(替爾泊肽,二型糖尿病) | $22.97B(229.7億美元) | 35.2% | +99% |
| Zepbound(替爾泊肽,肥胖) | $13.54B(135.4億美元) | 20.8% | +175% |
| Verzenio(abemaciclib,乳癌) | $5.72B(57.2億美元) | 8.8% | +8% |
| Trulicity(dulaglutide,二型糖尿病) | $4.28B(42.8億美元) | 6.6% | −19% |
| Taltz(ixekizumab,免疫) | $3.56B(35.6億美元) | 5.5% | +9% |
| Jardiance 系列(empagliflozin,與勃林格殷格翰合作) | $3.43B(34.3億美元) | 5.3% | +3% |
| 其他心臟代謝(含胰島素) | $4.01B(40.1億美元) | 6.1% | −10% |
| 其他腫瘤 | $3.65B(36.5億美元) | 5.6% | +6% |
| 其他免疫 | $1.68B(16.8億美元) | 2.6% | +49% |
| 神經科學 | $1.39B(13.9億美元) | 2.1% | −6% |
| 其他 | $0.94B(9.4億美元) | 1.4% | +4% |
| 合計 | $65.18B(651.8億美元) | 100% | +45% |
替爾泊肽(Mounjaro+Zepbound)就是整家公司——雙 GIP/GLP-1 受體促效劑,FY2025 營收 $36.5B(365億美元),佔 56%。Mounjaro(二型糖尿病,2022 年上市)拿下美國新增糖尿病處方逾 55%;Zepbound(肥胖,2023 年 11 月獲批)在美國新增品牌肥胖藥處方市佔近七成(70%),較便宜的小瓶裝已佔其處方約三分之一。
Verzenio(CDK4/6 抑制劑,乳癌)是腫瘤支柱,$5.72B(57.2億美元)仍在成長。Trulicity 是上一代每週一次 GLP-1,正被替爾泊肽蠶食——FY2025 下滑 19% 至 $4.28B(42.8億美元)。
Taltz(免疫)與 Jardiance 系列(與勃林格殷格翰合銷)是穩健的中個位數成長業務。「其他」項藏著下一波:免疫新藥 Omvoh、Ebglyss,腫瘤藥 Jaypirca,以及神經科學的抗類澱粉阿茲海默症藥 Kisunla。
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1876 | 南北戰爭老兵、藥劑化學家 Eli Lilly 上校在印第安納波利斯創立藥廠(1901 年註冊為 Eli Lilly and Company) |
| 1923 | 全球首家量產胰島素(Iletin),與多倫多大學研究團隊合作 |
| 1955 | 首家量產沙克小兒麻痺疫苗 |
| 1982 | Humulin 獲批——首個重組 DNA 人胰島素,也是首個生物科技藥物 |
| 1987 | 百憂解(Prozac,fluoxetine)獲批——成為重磅抗憂鬱藥 |
| 1996 | Zyprexa(olanzapine)獲批,治精神分裂症與躁鬱症 |
| 2003 | 犀利士(Cialis,tadalafil)獲批——成為勃起功能障礙重磅藥 |
| 2008 | 以約 $6.5B(65億美元)收購 ImClone Systems,取得癌症藥 Erbitux |
| 2014 | 以 $5.4B(54億美元)收購諾華動物保健業務,併入 Elanco |
| 2017 | David Ricks 接任執行長 |
| 2018 | 動物保健業務 Elanco 上市(9月) |
| 2019 | 以約 $8.0B(80億美元;每股 $235.00 現金,2019年1月7日宣布)收購 Loxo Oncology(2月);完成 Elanco 分拆(3月) |
| 2022 | Mounjaro(替爾泊肽)獲 FDA 批准治二型糖尿病(5月) |
| 2023 | Zepbound 獲批治慢性體重管理(11月,美國) |
| 2024 | Kisunla(donanemab)獲批治早期阿茲海默症(7月,美國);禮來成為全球市值最高藥廠 |
| 2025 | 替爾泊肽系列營收 $36.5B(365億美元,佔 56%);市值觸及 $1T(1兆美元,11月),全球首家醫療健康公司 |
| 2026 | Foundayo(orforglipron)——首個口服小分子 GLP-1——獲 FDA 批准治肥胖(4月);第二季營收 $22.97B(229.7億美元,同比 +48%)創紀錄;上調 FY2026 指引至 $85–87B(850–870億美元);宣布在賓州投資 $3.5B(35億美元)建注射劑廠(10月) |
競爭地位
財務快照 — FY2025
| 營收 | $65.18B(651.8億美元,同比 +45%;FY2024 $45.04B(450.4億美元)) |
| 毛利/毛利率 | $54.1B(541億美元)· 83.0% |
| 營業利潤 | $26.30B(263億美元)· 利潤率 40.4% |
| 淨利潤 | $20.64B(206.4億美元)· 淨利率 31.7%(同比 +95%) |
| 稀釋 EPS | $22.95(22.95美元,報表)· $24.21(24.21美元,非 GAAP,同比 +86%) |
| 研發費用 | $13.3B(133億美元,佔營收 20.4%) |
| 經營現金流 | $16.81B(168.1億美元;FY2024 $8.82B(88.2億美元)) |
| 自由現金流 | 約$6.0B(60億美元,經營現金流 $16.81B(168.1億美元) − 資本支出 $10.85B(108.5億美元)) |
| 現金及等價物 | $7.27B(72.7億美元,2025年12月31日) |
| 總債務 | 約$42.5B(425億美元)——淨負債狀態(債務權益比約 1.6 倍) |
| 股息 | $6.00(6.00美元)/股(同比 +15%)· 已付 $5.38B(53.8億美元) |
| 最新一季(2026 年第二季,截至2026年6月30日) | 營收 $22.97B(229.7億美元,同比 +48%)· 淨利潤 $7.10B(71億美元)· 稀釋 EPS $7.94(7.94美元)(非 GAAP $8.38(8.38美元))· 毛利率約 86% |
主要風險
對標普500的重要性
禮來是指數第 11 大成分股,權重 1.60%(2026年10月21日)——LLY 單獨波動 1%,標普500 大約動 1.6 個基點;按市值 $1,120B(1.12兆美元,2026年10月16日)是醫療健康板塊第一大公司。在科技主導的指數裡,禮來是醫療板塊的防禦成長錨:板塊風向標,貝塔低(約 0.43),也是市場上最純的肥胖藥週期曝險。
對指數與期權交易者:禮來每季財報(1 月底/4 月/7 月/10 月底)被市場當作 GLP-1 需求、定價與供應的定調,牽動 XLV 與整個醫療板塊;其與諾和諾德的處方市佔數據,是市場能拿到的最高頻腸泌素雙寡頭戰況。
來源與方法
| 財務、產品、員工、現金/債務 | 禮來 FY2025 Form 10-K(2026年2月申報;會計年度截至2025年12月31日);明細經 S&P Capital IQ(FT Markets)與 Alpha Spread |
| 產品營收拆分 | FY2025 10-K 產品披露(SEC 申報為本的彙整);Mounjaro/Zepbound 總額已與 2025 年第四季財報(2026年2月4日)交叉核對 |
| 最新一季(2026 年第二季) | 禮來 2026 年第二季財報(2026年8月5日);季度截至2026年6月30日 |
| 指數權重與排名 | Slickcharts 標普500權重,2026年10月21日收盤(任務基線) |
| 市值與板塊排名 | 2026年10月16日快照(SPXSet Top-25 數據集;任務基線) |
| 處方市佔、管線、指引 | 禮來 2025 年第四季財報電話會逐字稿(finviz);FY2026 指引 $85–87B(850–870億美元)營收,經 TipRanks(2026年10月20日) |
| 歷史與公司事實 | 禮來 10-K/10-Q/8-K 申報(經 findstockfast);維基百科公司條目(事實已與申報交叉核對) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-23 04:17 · updated 2026-11-14 23:46 · rev 17